Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography

Betül Okuyan; Fatih Tok; Sevgi Karakuş; Nazan Dalgıç; Erkan Çakır; Levent Midyat; Bedia Kaymakçıoğlu; Ufuk Erenberk; Fikret İzzettin; Sevim Rollas; Mesut Sancar

Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography

Abstract

The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients.

Keywords

References

[1] Pitucha M, Karczmarzyk Z, Swatko-Ossor M, Wysocki W, Wos M, Chudzik K, Ginalska G, Fruzinski A. Synthesis, in vitro screening and docking studies of new thiosemicarbazide derivatives as antitubercular agents. Molecules. 2019;24(2):251. [CrossRef]
[2] Nguyen PC, Delorme V, Bénarouche A, Guy A, Landry V, Audebert S, Pophillat M, Camoin L, Crauste C, Galano JM, Durand T, Brodin P, Canaan S, Cavalier JF. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. Bioorg Chem. 2018;81:414-424. [CrossRef]
[3] Castelo-Branco FS, de Lima EC, Domingos JLO, Pinto AC, Lourenço MCS, Gomes KM, Costa-Lima MM, Araujo-Lima CF, Aiub CAF, Felzenszwalb I, Costa TEMM, Penido C, Henriques MG, Boechat N. New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity. Eur J Med Chem. 2018;146:529-540. [CrossRef]
[4] Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
[5] Igarashi M. Development of new antituberculosis drugs from natural products. Biosci Biotechnol Biochem. 2017;81(1):32-37. [CrossRef]
[6] Halicki PCB, Ferreira LA, De Moura KCG, Carneiro PF, Del Rio KP, Carvalho TDSC, Pinto MCFR, Silva PEA, Ramos DF. Naphthoquinone derivatives as scaffold to develop new drugs for tuberculosis treatment. Front Microbiol. 2018;9:673. [CrossRef]
[7] Ugwu DI, Ezema BE, Eze FU, Ugwuja DI. Synthesis and structural activity relationship study of antitubercular carboxamides. Int J Med Chem. 2014; 2014:614808. [CrossRef]
[8] Zheng Y, Xu N, Hu X, Zhang Q, Liu Y, Zhao Q. Development and application of a LC-MS/MS method for simultaneous quantification of four first-line antituberculosis drugs in human serum. J Anal Methods Chem. 2020;2020:8838219. [CrossRef]

[9] Oliveira JRS, Shiguemoto CYK, Neves AR, Moreira FMF, Gomes GB, Perdomo RT, Barbosa SL, Guerrero PG, Croda J, Baroni ACM. Design, synthesis and antitubercular activity of novel isoniazid-cyclic-amine-azachalcones hybrids. J Braz Chem Soc. 2020;31(6):1284-1295. [CrossRef]
[10] Martinez R, Zamudio GJN, Pretelin-Castillo G, Torres-Ochoa RO, Medina-Franco JL, Pinzon CIE, Miranda MS, Hernandez E, Alanis-Garza B. Synthesis and antitubercular activity of new N-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-(nitroheteroaryl)carboxamides. Heterocycl. Commun. 2019;25:52–59. [CrossRef]
[11] Johannessen Landmark C, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol. 2020;16(3):227-238. [CrossRef]
[12] Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Perez D, Chaparro G, Gonzalez F, Aarnoutsa RE, Alffenaar JW, Magis-Escurra C. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of antituberculosis drugs in children. Int J Antimicrob Agents. 2018;52(1):109-113. [CrossRef]
[13] Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutsa RE, Magis-Escurra C, Kosterink JGW, Werf TS, Alffenaar JWC, Sturkenboom MGG. Optimal sampling strategies for therapeutic drug monitoring of first-line tuberculosis drugs in patients with tuberculosis. Clin Pharmacokinet. 2019;58(11):1445-1454. [CrossRef]
[14] Märtson AG, Burch G, Ghimire S, Alffenaar JWC, Peloquin CA. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol. 2021;17(1):23-39. [CrossRef]
[15] Babalik A, Mannix S, Francis D, Menzies D. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225-229. [CrossRef]
[16] Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, Lange W, Soolingen D, Alffenaar JWC. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2016;12(5):509-521. [CrossRef]
[17] Seddon JA, Furin JJ, Gale M, Del Castillo Barrientos H, Hurtado RM, Amanullah F, Ford N, Starke JR, Schaaf HS, Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med. 2012;186(10):953-964. [CrossRef]
[18] Wróblewski K, Petruczynik A, Tuzimski T, Prajsnar K, Przygodzka D, Buszewicz G, Karakula-Juchnowicz H, Rog J, Morylowska-Topolska J, Waksmundzka-Hajnos M. Optimization of chromatographic systems for analysis of selected psychotropic drugs and their metabolites in serum and saliva by HPLC in order to monitor therapeutic drugs. Open Chem. 2019;17:1361-1373. [CrossRef]
[19] Unsalan S, Sancar M, Bekce B, Clark PM, Karagoz T, Izzettin FV, Rollas S. Therapeutic monitoring of isoniazid, pyrazinamide and rifampicin in tuberculosis patients using LC. Chromatographia. 2005;61:595-598. [CrossRef]
[20] Verhagen LM, Lopez D, Hermans PWM, Warris A, Groot R, Garcia JF, Waard JH, Aarnoutse RE. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. Trop Med Int Health. 2012;17(12):1449-1456. [CrossRef]
[21] Tahan TT, Gabardo BMA, Rossoni AMO. Tuberculosis in childhood and adolescence: a view from different perspectives. J Pediatr (Rio J). 2020;96(1):99-110. [CrossRef]
[22] McIlleron H, Chirehwa MT. Current research toward optimizing dosing of first-line antituberculosis treatment. Expert Rev Anti Infect Ther. 2019;17(1):27-38. [CrossRef]
[23] Dayal R, Singh Y, Agarwal D, Kumar M, Swaminathan S, Ramachandran G, Kumar S, Narayan S, Goyal A, Kumar AKH. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status. Arch Dis Child. 2018;103(12):1150-1154. [CrossRef]
[24] Hemanth Kumar AK, Kumar A, Kannan T, Bhatia R, Agarwal D, Kumar S, Dayal R, Singh SP, Ramachandran G. Pharmacokinetics of second-line antituberculosis drugs in children with multidrug-resistant tuberculosis in India. Antimicrob Agents Chemother. 2018;62(5):02410-02417. [CrossRef]
[25] Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Ortsin A, Dompreh A, Yang H, Wiesner L, Peloquin CA. Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrob Agents Chemother. 2018;62(9):00008-00018. [CrossRef]
[26] Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother. 2016;60(4):2171-2179. [CrossRef]
[27] Cruz AT, Starke JR. Monitoring treatment of childhood tuberculosis and the role of therapeutic drug monitoring. Indian J Pediatr. 2019;86(8):732-739. [CrossRef]

Details

Primary Language

English

Subjects

Pharmaceutical Analytical Chemistry, Pharmacology and Pharmaceutical Sciences (Other)

Journal Section

Research Article

Authors

Betül Okuyan
Türkiye

Fatih Tok
Türkiye

Sevgi Karakuş
Türkiye

Nazan Dalgıç
Türkiye

Erkan Çakır
Türkiye

Levent Midyat This is me
Türkiye

Bedia Kaymakçıoğlu
Türkiye

Ufuk Erenberk This is me
Türkiye

Fikret İzzettin
Türkiye

Sevim Rollas
Türkiye

Mesut Sancar ^*
Türkiye

Publication Date

June 28, 2025

Submission Date

July 15, 2022

Acceptance Date

September 5, 2022

Published in Issue

Year 2022 Volume: 26 Number: 6

IZ

https://izlik.org/JA42BA44HR

Cite

RIS / Bibtex

APA

Okuyan, B., Tok, F., Karakuş, S., Dalgıç, N., Çakır, E., Midyat, L., Kaymakçıoğlu, B., Erenberk, U., İzzettin, F., Rollas, S., & Sancar, M. (2025). Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography. Journal of Research in Pharmacy, 26(6), 1907-1914. https://izlik.org/JA42BA44HR

AMA

1.Okuyan B, Tok F, Karakuş S, et al. Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography. J. Res. Pharm. 2025;26(6):1907-1914. https://izlik.org/JA42BA44HR

Chicago

Okuyan, Betül, Fatih Tok, Sevgi Karakuş, et al. 2025. “Therapeutic Drug Monitoring in Pediatric Patients Treated With Anti-Tuberculosis Medications by High Performance Liquid Chromatography”. Journal of Research in Pharmacy 26 (6): 1907-14. https://izlik.org/JA42BA44HR.

EndNote

Okuyan B, Tok F, Karakuş S, Dalgıç N, Çakır E, Midyat L, Kaymakçıoğlu B, Erenberk U, İzzettin F, Rollas S, Sancar M (June 1, 2025) Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography. Journal of Research in Pharmacy 26 6 1907–1914.

IEEE

[1]B. Okuyan et al., “Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography”, J. Res. Pharm., vol. 26, no. 6, pp. 1907–1914, June 2025, [Online]. Available: https://izlik.org/JA42BA44HR

ISNAD

Okuyan, Betül - Tok, Fatih - Karakuş, Sevgi - Dalgıç, Nazan - Çakır, Erkan - Midyat, Levent - Kaymakçıoğlu, Bedia et al. “Therapeutic Drug Monitoring in Pediatric Patients Treated With Anti-Tuberculosis Medications by High Performance Liquid Chromatography”. Journal of Research in Pharmacy 26/6 (June 1, 2025): 1907-1914. https://izlik.org/JA42BA44HR.

JAMA

1.Okuyan B, Tok F, Karakuş S, Dalgıç N, Çakır E, Midyat L, Kaymakçıoğlu B, Erenberk U, İzzettin F, Rollas S, Sancar M. Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography. J. Res. Pharm. 2025;26:1907–1914.

MLA

Okuyan, Betül, et al. “Therapeutic Drug Monitoring in Pediatric Patients Treated With Anti-Tuberculosis Medications by High Performance Liquid Chromatography”. Journal of Research in Pharmacy, vol. 26, no. 6, June 2025, pp. 1907-14, https://izlik.org/JA42BA44HR.

Vancouver

1.Betül Okuyan, Fatih Tok, Sevgi Karakuş, Nazan Dalgıç, Erkan Çakır, Levent Midyat, Bedia Kaymakçıoğlu, Ufuk Erenberk, Fikret İzzettin, Sevim Rollas, Mesut Sancar. Therapeutic Drug Monitoring in Pediatric Patients Treated with Anti-Tuberculosis Medications by High Performance Liquid Chromatography. J. Res. Pharm. [Internet]. 2025 Jun. 1;26(6):1907-14. Available from: https://izlik.org/JA42BA44HR